Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Chantix on Relapse Prevention for Smoking Cessation

This study has been completed.
Sponsor:
Collaborator:
AstraZeneca
Information provided by:
University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00948649
First received: July 28, 2009
Last updated: August 16, 2010
Last verified: July 2009